AMEX · OSTX

OS Therapies Incorporated

$1.52 -$0.04 (-2.56%) 1D After hours

Key Metrics

$69.48M
Market cap
P/E · TTM
Revenue · TTM
−$35.27M
Net income
EPS · TTM $-1.66
Dividend yield
Free cash flow
Beta · 1Y 1.63
EBITDA · TTM
Gross margin

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Jul 8
    From its Jun 29 high, the share price fell 35%.

    Peak close $2.24 on Jun 29; trough close $1.46 on Jul 8. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -35%
  • Jun 29
    The stock moved +19.1% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jun 29
  • Apr 24
    The stock moved +22.1% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Apr 24

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$69.48M
Enterprise value
Shares outstanding44.5M
52-wk range$1.15 – $2.57
Avg volume · 20D532.0K
Net cash
Book value / share$-0.51
IndustryPharmaceutical Preparations
ExchangeAMEX
About OS Therapies Incorporated
IPO dateAug 1, 2024
Employees5

OS Therapies Inc is a clinical stage biopharmaceutical company focused on the identification, development and commercialization of treatments for Osteosarcoma (OS) and other solid tumors.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S
P/FCF
EV/EBITDA
EV/Sales
Graham №

Profitability

Gross
Operating
Net
FCF
ROE / ROIC 439.2% · —

Financial Health

Current ratio0.05
Quick ratio
Debt / equity
Debt / EBITDA
Net cash
Working capital−$16.04M

Cash Flow · TTM

Operating CF −$15.36M
Capex
Free cash flow
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

1 / 9
Weak fundamentals · 1 of 9 signals passing

Altman Z-Score

Insufficient balance-sheet inputs

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings